A survey conducted found that patients overwhelmingly prefer that the FCS physicians, nurses and staff members are vaccinated and wear masks to reduce the spread of COVID-19.
In response to growing concerns amidst the statewide surge of COVID-19 variants, FCS will require all physicians and team members to be fully vaccinated by October 1, 2021.
The in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.
Medical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Dr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”
Lucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Medical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”
FCS Top News Updates
FCS Expands Clinical Team in Lake County, Welcomes Aamir Hussain to Statewide Practice
Florida Cancer Specialists & Research Institute Survey Finds Cancer Patients Support COVID-19 Vaccine & Mask MandateA survey conducted found that patients overwhelmingly prefer that the FCS physicians, nurses and staff members are vaccinated and wear masks to reduce the spread of COVID-19.
Florida Cancer Specialists & Research Institute to mandate COVID-19 vaccines for its workforceIn response to growing concerns amidst the statewide surge of COVID-19 variants, FCS will require all physicians and team members to be fully vaccinated by October 1, 2021.
Florida Cancer Specialists & Research Institute Oral Oncolytic Pharmacy Earns Dual NABP Pharmacy AccreditationsThe in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.
James Reeves, MD Co-Authors Abstract Evaluating Abemaciclib Combined with Adjuvant Endocrine Therapy in Patients with High Risk Early Breast CancerMedical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Hugo Davila, MD Is Lead Author of Study Evaluating the Pubocervical Fascia in Female Pelvic Organ ProlapseDr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”
Lucio Gordan, MD and Michael Diaz, MD Are Co-Authors of In-Depth Review on Medicare Part B ReimbursementLucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute Studies Featured at ASCO® 2021 Annual MeetingFlorida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Syed Zafar, MD Co-Authors Study on Adjuvant Nivolumab in Esophageal/Gastroesophageal Junction CancerMedical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”